# A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis

> **NCT03165435** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **CuraVac**

## Conditions studied

- Myasthenia Gravis, Generalized

## Interventions

- **BIOLOGICAL:** CV-MG01
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03165435
- **Lead sponsor:** CuraVac
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-07
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Not enough participating centres to complete recruitment in a timely manner.
- **Last updated:** 2018-05-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03165435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03165435, "A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03165435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*